http://rdf.ncbi.nlm.nih.gov/pubchem/patent/TW-201514129-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ba10f882a347602cac65ced0d60d6fed |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07B63-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07B59-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/B01D15-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 |
| filingDate | 2013-10-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d32e2b0167de4b9f06e2a6be616e09f2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3dcb96ccd50576d1c07426117b70f02c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_62e058affe8013cebe8b19871edc37f4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_62c5d06a469482c8a89c43f8676334cb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d52052fe89a62319f5847fa109d0a67a |
| publicationDate | 2015-04-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | TW-201514129-A |
| titleOfInvention | Improved fluorine-18-Flumazenil label and separation and purification method |
| abstract | An improved fluorine-18-Flumazenil label and separation and purification method for producing molecular probes for central nervous system gamma aminobutyric acid (GABA) type A receptors. Flumazenil, which is marked by fluorine-18, has GABAAnThe brain regions of the receptors have high binding forces and can therefore be used as a tracer to observe these regions. The invention reduces the reaction time of the label process to 15 minutes, the temperature is reduced to 150 ° C, and does not affect the yield, and also uses the ethanol instead of the separation and purification process, which may use the poison acetonitrile and the subsequent removal of acetonitrile. process. This makes the operation easier and saves time. In addition, the fluoro-18-Flumazenil product of the present invention has been shown to pass through the cerebral vascular barrier after animal imaging experiments and to GABAA in the animal brain.nReceptors have a relatively high affinity, and in the future, they can be applied to the evaluation of drug efficacy in related mental illnesses such as anxiety, schizophrenia, and epilepsy. It is expected to effectively shorten the time course of drug development for central nervous system related diseases. |
| priorityDate | 2013-10-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 55.